Vanguard Group Inc's Amendment to Schedule 13G for Monte Rosa Therapeutics Inc

The Vanguard Group Inc has filed an amendment to its Schedule 13G for Monte Rosa Therapeutics Inc, reporting ownership of 2,988,953 shares, which represents 4.83% of the company's common stock. The filing indicates that Vanguard's clients, including investment companies and managed accounts, have the right to receive dividends or proceeds from the sale of these securities. The amendment also states that no single client owns more than 5% of the securities. The filing was signed by Ashley Grim, Head of Global Fund Administration, on October 31, 2025. The amendment reflects a decrease of 151,557 shares from the previous filing, with the value of the holdings increasing by 171.17% to $38,408,046.05.